Low‐grade serous carcinomas of the ovary contain very few point mutations

It has been well established that ovarian low‐grade and high‐grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high‐grade serous carcinomas are now well known, the pathogenesis of low‐grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low‐grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity‐purified, low‐grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low‐grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low‐grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38%) and 5 (19%) of 27 low‐grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low‐grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[2]  I. Shih,et al.  Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma , 2011, The American journal of surgical pathology.

[3]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[4]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[5]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[6]  S. Mok,et al.  BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. , 2010, The American journal of pathology.

[7]  D. Heimbrook,et al.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.

[8]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[9]  Carl Virtanen,et al.  Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. , 2010, Gynecologic oncology.

[10]  P. Rosenberg,et al.  Qualitative Age Interactions between Low-grade and High-grade Serous Ovarian Carcinomas , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[11]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[12]  I. Shih,et al.  Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. , 2009, Cancer research.

[13]  M. Fukumoto,et al.  KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer , 2008, British Journal of Cancer.

[14]  S. Plaxe Epidemiology of low-grade serous ovarian cancer. , 2008, American journal of obstetrics and gynecology.

[15]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[16]  I. Shih,et al.  The Development of High-grade Serous Carcinoma From Atypical Proliferative (Borderline) Serous Tumors and Low-grade Micropapillary Serous Carcinoma: A Morphologic and Molecular Genetic Analysis , 2007, The American journal of surgical pathology.

[17]  D. Bodurka,et al.  Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. , 2007, Gynecologic oncology.

[18]  U. Löhrs,et al.  KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. , 2006, Gynecologic oncology.

[19]  A. Sood,et al.  Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary , 2006, Obstetrics and gynecology.

[20]  L. Cope,et al.  Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms , 2006, Cancer biology & therapy.

[21]  I. Shih,et al.  Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges , 2005, Clinical Cancer Research.

[22]  Tian-Li Wang,et al.  Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. , 2005, Cancer research.

[23]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[24]  Chung-Liang Ho,et al.  Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas , 2004, Clinical Cancer Research.

[25]  Chung-Liang Ho,et al.  Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors , 2004, Cancer Research.

[26]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[27]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[28]  A. Flanagan,et al.  In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.

[29]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[30]  M. Sherman,et al.  Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. , 1996, The American journal of surgical pathology.

[31]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[32]  Illinois.,et al.  Cancer Genetics , 1976, British Journal of Cancer.

[33]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[34]  M. Gordon,et al.  RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models , 2010 .

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.